Sei Investments Co. Has $534,000 Holdings in Amicus Therapeutics, Inc. (FOLD)

Sei Investments Co. raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 14,616.4% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 34,142 shares of the biopharmaceutical company’s stock after purchasing an additional 33,910 shares during the period. Sei Investments Co.’s holdings in Amicus Therapeutics were worth $534,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in Amicus Therapeutics by 9.7% in the 1st quarter. Rhumbline Advisers now owns 173,506 shares of the biopharmaceutical company’s stock valued at $2,610,000 after purchasing an additional 15,275 shares during the last quarter. Mackay Shields LLC acquired a new position in Amicus Therapeutics in the 1st quarter valued at about $993,000. American Century Companies Inc. raised its stake in Amicus Therapeutics by 138.9% in the 1st quarter. American Century Companies Inc. now owns 239,386 shares of the biopharmaceutical company’s stock valued at $3,600,000 after purchasing an additional 139,179 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Amicus Therapeutics by 11.7% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 765,421 shares of the biopharmaceutical company’s stock valued at $11,512,000 after purchasing an additional 80,306 shares during the last quarter. Finally, Swiss National Bank raised its stake in Amicus Therapeutics by 28.0% in the 1st quarter. Swiss National Bank now owns 322,900 shares of the biopharmaceutical company’s stock valued at $4,856,000 after purchasing an additional 70,700 shares during the last quarter.

In related news, major shareholder Life Sciences Maste Perceptive acquired 500,000 shares of the company’s stock in a transaction dated Wednesday, September 12th. The stock was bought at an average price of $12.00 per share, with a total value of $6,000,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Kurt J. Andrews sold 5,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $15.63, for a total transaction of $78,150.00. Following the transaction, the senior vice president now directly owns 40,469 shares of the company’s stock, valued at approximately $632,530.47. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Shares of FOLD stock opened at $11.74 on Friday. Amicus Therapeutics, Inc. has a twelve month low of $11.57 and a twelve month high of $17.62. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.73 and a current ratio of 10.88.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.33). Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. The company had revenue of $21.31 million during the quarter, compared to the consensus estimate of $18.92 million. equities research analysts predict that Amicus Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Several research analysts recently weighed in on FOLD shares. BidaskClub raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 19th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Tuesday, July 10th. ValuEngine downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 19th. Finally, Chardan Capital downgraded shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $18.00 to $15.00 in a research note on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $19.43.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Article: Asset Allocation

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply